potentially long, after triangle breako www.tradingview.com ut
MEIP has AML data OS > 22 months, which is a very very good one. The stock goes died since mid 2015 because of another drug phase 2 failure. The AML one would go to phase 3 in the second half of this year. I think this would be a big one if we catch it. The consolidation has been happening for a while.
1) Bollinger bounce - closes lower outsides of the band with lighter volume 75% drop in volume 2) Possible MA Cross in uptrend sequence 3) MACD line crosses up through the average line
MEIP expected to open at 5.39 for a Retest Gap. Be aware of low volume and low $ stock To learn to trade this strategy for free go to www.RealLifeTrading.com
MEI Pharma, Inc. (MEIP), will be presenting data on Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) at a poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012. Stock looks good for at least a $.50 pop